Generally, two main approaches to generating labeled peptides are synthesizing the peptide with labeled amino acids incorporated or adding the label post-synthesis. Incorporating labeled amino acids during synthesis is typically preferred, as it ensures the label is positioned correctly within the peptide structure. However, challenges may arise, such as issues with the solubility of the peptide epitopes, especially for longer sequences​ (LifeTein)​.

A specific example of this strategy’s application is the synthesis of peptides with a C-terminal biotin-labeled lysine. In one approach, a peptide was synthesized on Rink amide MBHA resin coupled with Fmoc-Lys(Dde)-OH, allowing for subsequent labeling of the peptide’s side chain. This technique ensures the label, such as biotin, is precisely added to a designated site on the peptide, following peptide synthesis and prior to its cleavage from the resin​ (LifeTein)​.

This approach exemplifies the versatility and efficacy of using solid-phase peptide synthesis (SPPS) for creating specifically labeled peptides for various research purposes. By selecting appropriate protecting groups and resin, researchers can streamline the synthesis of peptides with desired labels, enhancing their utility in biological studies​ (LifeTein)​.

For more detailed insights into this peptide synthesis strategy’s process and potential applications, visiting sources such as LifeTein’s overview on peptide synthesis could provide valuable information and guidance​ (LifeTein)​.

Boosting Immunogenicity: Due to their relatively small size, many peptides inherently possess low immunogenic potential. Attaching these peptides to carrier proteins such as Keyhole Limpet Hemocyanin (KLH), Bovine Serum Albumin (BSA), or Ovalbumin (OVA) not only augments the molecular size of the antigen but also significantly enhances its capability to induce an immune response. The inclusion of a cysteine residue within the peptide sequence is often recommended to facilitate efficient and stable conjugation to the carrier protein.

Activating T Cells: The introduction of carrier proteins in conjugate vaccines is crucial for activating T cells, essential players in the adaptive immune system. These proteins enable the antigen to be more effectively recognized, processed, and presented by antigen-presenting cells, thus eliciting a more vigorous T-cell-mediated response.

Facilitating Isotype Switching: The conjugation process also influences isotype switching within B cells. This is significant because various antibody isotypes perform distinct functions within the immune system. By guiding the immune response toward producing a particular antibody isotype, conjugation can tailor the body’s defense mechanism against specific pathogens.

Inducing Memory Responses: Another advantage of conjugate vaccines is their ability to stimulate a memory response from the immune system. This memory function ensures that the immune system can quickly and efficiently react to future exposures to the pathogen, offering long-term immunity.

Preventing Immune Tolerance: Repeated exposure to a peptide antigen alone may lead to immune tolerance, diminishing the immune system’s responsiveness to the antigen. Conjugating the peptide to a carrier protein can avert this tolerance, maintaining the immune system’s vigilance against the antigen.

Improving Stability and Solubility: The stability and solubility of peptides, particularly synthetic ones, can be limited. Conjugation improves these properties, enhancing the antigen’s usability in vaccine formulations.

Facilitating Regulatory Approval: The successful development and approval of conjugate vaccines against pathogens like Haemophilus influenzae type b and Streptococcus pneumoniae highlight the importance of carrier proteins in vaccine safety and efficacy, which is often a requirement for regulatory approval.

Expanding on the choice of carrier proteins, each has unique properties that may influence the immune response. For example, KLH is highly immunogenic and soluble, making it a preferred choice for many applications. BSA and OVA are also widely used, offering different advantages such as availability and cost-effectiveness. The selection of a carrier protein can depend on various factors, including the intended use of the antibody, the need for cross-species reactivity, and the specific requirements of the antigen.

The strategic use of carrier proteins in the conjugation of peptides is a pivotal step in designing and developing effective vaccines and antibodies. This approach amplifies the immune response and ensures specificity, stability, and a lasting defense against pathogens, underscoring its essential role in modern immunology and vaccine science.

The label biotin is conjugated with the peptide before cleaving from the resin. After purification, we have no way to conjugate it with the peptide. We need to quote as two different peptides as purification will be performed differently.

I. Introduction

A. Brief Explanation of Competitive ELISA

Competitive Enzyme-Linked Immunosorbent Assay (ELISA) is a powerful technique used in immunology and molecular biology to determine the concentration of an antigen in a sample. Unlike traditional ELISA, competitive ELISA involves competition between the sample antigen and a known labeled antigen (often a peptide) for binding to a limited amount of immobilized antibodies.

B. Importance of Using Peptides in Competitive ELISA

Peptides, short chains of amino acids, are commonly used in competitive ELISA due to their specificity and ease of synthesis. They offer a cost-effective alternative to complete proteins for antigen-binding studies.

C. Overview of What the Article Will Cover

This article will guide you through performing Competitive ELISA using peptides, from selecting the right peptides to data analysis and troubleshooting common issues.

Sample steps:

1. ELISA plates were coated with 100 μl of the mutant peptide (200 ng/ml) overnight.
2. After blocking plates with PBS with 1% BSA for 1 h, the peptide-specific monoclonal antibodies (10 ng/ml) pre-incubated overnight with varying concentrations (0–1,000 μg/ml) of native peptides in PBS with 1% BSA was added to the mutant peptide-coated plates, and we performed ELISA as described above.
3. For the alanine scanning mutagenesis experiments, competitive ELISA was performed as described above using peptide variants.

II. Understanding Competitive ELISA

A. Explanation of ELISA as an Immunoassay Technique

ELISA involves the use of antibodies to detect and quantify antigens. Competitive ELISA employs competition between the sample antigen and a labeled antigen for antibody binding.

B. Key Components and Reagents Needed for Competitive ELISA

• Microtiter plates
• Antigen-coating buffer
• Blocking solution
• Primary antibodies
• Labeled peptide antigen
• Substrate for detection

C. Why Peptides Are Ideal for Competitive Assays

Peptides are highly specific and can mimic antigenic regions of proteins. They are also relatively easy to synthesize, modify, and purify.

III. Selecting the Right Peptides

A. Importance of Peptide Selection

Careful selection of peptides is crucial for a successful assay. Consider antigenicity, uniqueness, and relevance to your research.

B. Types of Peptides Used in Competitive ELISA

• Linear peptides
• Discontinuous peptides (conformational epitopes)
• Synthetic peptides
• Recombinant peptides

C. Tips for Designing or Sourcing Peptides

• Design peptides with unique sequences (See details on how to design peptide antigen).
• Verify peptide purity and quality.
• Consider modifications for better binding affinity.

IV. Coating and Blocking

A. Preparing the Microtiter Plate

• Coat wells with antigen-coating buffer.
• Incubate at the recommended temperature.

B. Coating the Plate with Antigen

• Add the diluted peptide solution.
• Incubate to allow binding.
• Wash to remove unbound peptides.

C. Blocking Non-Specific Binding Sites

• Add blocking solution.
• Incubate to prevent non-specific binding.

V. Preparing Standards and Samples

A. Diluting Peptides and Standards

• Create a series of standard peptide concentrations.
• Dilute samples as needed.

B. Proper Sample Preparation Techniques

• Avoid contamination.
• Maintain sample integrity.

C. Importance of Controls in Competitive ELISA

Include positive and negative controls to validate your assay.

VI. Incubation and Competition

A. How the Competitive Reaction Works

• Mix sample and labeled peptide.
• Incubate to allow competition for antibody binding.

B. Optimizing Incubation Times and Temperatures

• Follow recommended times and temperatures.
• Perform pilot experiments for optimization.

C. Factors Affecting Competition and Binding

pH, ionic strength, and antibody concentration can impact binding efficiency.

VII. Detection and Measurement

A. Introduction to Detection Methods

• Choose a detection method (e.g., colorimetric, chemiluminescent).
• Follow manufacturer instructions.

B. How to Quantify Competitive Binding

Measure signal intensity or absorbance.

C. Data Analysis and Interpretation

• Generate a standard curve.
• Calculate sample concentrations.

VIII. Troubleshooting Common Issues

A. Addressing High Background Signals

• Adjust blocking conditions.
• Optimize washing steps.

B. Dealing with Low Sensitivity

• Increase antigen concentration.
• Adjust antibody dilutions.

C. Strategies for Improving Specificity

• Use more specific antibodies.
• Validate results with alternative methods.

IX. Advanced Tips and Techniques

A. Enhancing Assay Sensitivity and Dynamic Range

Modify assay conditions for improved sensitivity.

B. Multiplexing Competitive ELISA

Simultaneously measure multiple antigens.

C. Customizing Competitive ELISA for Unique Applications

Adapt the assay to suit your specific research needs.

X. Applications and Case Studies

A. Real-World Examples of Competitive ELISA Using Peptides

Highlight case studies showcasing the versatility and utility of the technique.

1. In order to detect PD-L1 in tissues, a biotin-conjugated version of peptide RK-10-Cy5 was used.
2. Tissues were incubated with 15 µM biotinylated peptide for 2 hours.
3. After 2 hours, slides were washed with buffer and treated with Pierce™ High Sensitivity Streptavidin-HRP (1:200 dilution) for 30 minutes.
4. Once this was complete, slides were again washed in buffer then treated with DAB (Sigma) for 10 minutes. Slides were again washed in buffer, then dehydrated using graded alcohol and xylene and counterstained with hematoxylin.
5. Slides were then imaged using bright-field microscopy on a Leica DM5500.

Coating the appropriate antigen to microplate
1. Dilute the antigen to a final concentration of 20 μg/ml in PBS. Fill the microwells of a Nunc Maxi-Sorp Immuno Plate with 50 μL of the diluted antigen.
Note: Test samples containing pure antigen are usually pipetted onto the plate at less than 2μg/ml. Antigen protein concentration should not be over 20 μg/ml as this will saturate most of the available sites on the microtitre plate.
2. Incubate at 4°C overnight or 2 h at room temperature.
3. Wash the unbound antigen off the plate by flicking the contents of the plate into the sink, fill the wells with DI water, flick again, repeat 2X with PBS-Triton.

Blocking
4. Block the remaining protein-binding sites in the coated wells by adding 200 μl blocking buffer, 1% BSA/PBS, or other blocking reagents.
5. Incubate for 30-60 minutes at Room Temperature (RT) or 4°C overnight.
6. Wash plate as above.
Incubation with the antibody
7. Add 100μl of the antibody, diluted at the optimal concentration in blocking buffer immediately before use.
Note: Be sure to include positive and negative controls, and, if necessary, a standard curve.
8. Incubate for 2h at room temperature.
Note: 2hours is usually enough to obtain a strong signal. Stronger staining will often be observed when incubated overnight at 4°C.
9. Wash the plate 4 times with PBS.

Detection
10. Dispense 100 μl (or 50 μl) of the substrate solution per well with a multichannel pipet.
11. After sufficient color development adds 100 μl of stop solution to the wells.
12. Read the absorbance (optical density) of each well with an ELISA plate reader.

Common Substrates and the appropriate plate reader setting
· ABTS: 405-410 nm
· TMB: non-stopped 620-650 nm, stopped 450 nm
· OPD: non-stopped 450 nm, stopped 490 nm
· pNPP: 405-410 nm
· BluePhos: 595-650 nm

Buffers and reagents
Bicarbonate/carbonate coating buffer (100 mM)
3.03 g Na2CO3,6.0 g NaHCO3, 1000 ml distilled water pH 9.6,
PBS
1.16 g Na2HPO4, 0.1 g KCl, 0.1 g K3PO4, 4.0 g NaCl (500 ml distilled water) pH 7.4.

Blocking solution
1% BSA, serum, non-fat dry milk, casein, gelatin in PBS.

Wash solution
PBS or Tris-buffered saline (pH 7.4) with 0.05% (v/v) Tween20 (TBST) or Triton.

Antibody dilution buffer
Primary and secondary antibody should be diluted in 1x blocking solution to reduce nonspecific binding.

Standards and the standard curve
1. Make up a stock solution of 0.08 ug of protein/100 ul of PBS and store at 4 C

To make the stock:

• Use protein extracted from fresh hyphae that are nearly 100% immunoreactive. To determine this, run a Bradford and an ELISA assay on the samples and compare concentrations.
• If Bradford and ELISA values are nearly the same, make an ELISA curve and test the values by comparing results to a known curve.
• Make up 500 ul aliquots of the stock with a concentration of 0.08 ug of protein in 100 ul of PBS or 0.40 ug of protein in 500 ul of PBS.

2. Put 100 ul of the 0.08 ug protein/100 ul of PBS in 2 of the wells and 50 ul PBS in the other ten wells.
3. Transfer 50 ul of the 0.08 ug sample to a neighboring well that has 50 ul PBS.
4. Mix 3-4 times with the micropipette by pulling the sample up and down.
5. Remove 50 ul from these two wells and transfer to 2 adjacent wells. Mix 3-4x. Repeat for these two wells.
6. After the third dilution, remove 50 ul from the two wells that have 100 ul and dispose of it.

Western blotting is an important technique used in cell and molecular biology. Researchers can identify specific proteins from a complex mixture of proteins extracted from cells using Western Blot.

A mixture of proteins is separated based on molecular weight through gel electrophoresis. The gels are then transferred to a membrane producing a band for each protein. The membrane is then incubated with labels antibodies specific to the protein of interest. The bound antibodies are then detected by developing the film.
The multi-tag positive loading control protein is used to demonstrate that your Western Blot protocol is efficient and correct and that the antibody recognizes the target protein which may not be present in the experimental samples. Loading such protein into your positive control lane results in a reliably detectable protein sample. It means all the steps of your Western blot functioned adequately, including gel electrophoresis, protein transfer to a blotting membrane, membrane blocking, and antibody labeling. It also gives you greater confidence that the results in the other lanes are real rather than artifactual.

We strongly recommend the use of a positive control protein when setting up a new experiment; this will give you immediate confidence in your Western Blot protocol.

When trying to detect low-abundance proteins, it is especially important to know that your Western blot is functioning as expected. If you detect your protein of interest in the control lane, then an absence of the protein in other lanes is probably directly related to its low abundance rather than a faulty step in the blotting protocol.

Highlights:

• Demonstrate that your protocol is efficient and correct.
• Perfect positive control protein for your Western blotting.
• Save time and resources for all your protein research projects.
• Give you confidence in your Western blot protocol.
• Can be used for immuno-precipitation, affinity purification, Western blot and dot blot.

Order this positive loading control protein now: https://lifetein.com/peptide-product/multitag-protein-p-1.html
This paper provides the theoretical explanation of the Western Blotting procedure, troubleshooting tips for common problems: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3456489/
Troubleshooting: (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3456489/)

Even though the procedure for western blot is simple, there could be many unexpected results:
(1) Unusual or unexpected bands
(2) No bands
(3) Faint bands or weak signal
(4) High background on the blot
(5) Patchy or uneven spots on the blot
(6) Non-fat milk or BSA

(1) Unusual or unexpected bands: These can be due to protease degradation, which produces bands at unexpected positions. It is advisable to use a fresh sample that had been kept on ice or alter the antibody. If the protein seems to be in too high of a position, then reheating the sample can help to break the quaternary protein structure. Similarly, blurry bands are often caused by high voltage or air bubbles present during transfer. In this case, it should be ensured that the gel is run at a lower voltage and that the transfer sandwich is prepared properly. Also, changing the running buffer can also help the problem. Nonflat bands can be the result of too fast of travel through the gel, due to low resistance. To fix this, the gel should be optimized to fit the sample. Finally, white (negative) bands on the film are due to too much protein or antibody.

(2) No bands: This is due to many reasons related to the antibody, antigen, or buffer used. If an improper antibody is used, either primary or secondary, the band will not show. Also, the concentration of the antibody should be appropriate as well; if the concentration is too low, the signal may not be visible. It is important to remember that some antibodies are not to be used for western blot. Another reason for no visible bands is the lowest concentration or absence of the antigen. In this case, an antigen from another source can be used to confirm whether the problem lies with the sample or with other elements, such as the antibody. Moreover, prolonged washing can also decrease the signal. Buffers can also contribute to the problem. It should be ensured that buffers like the transfer buffer, TBST, running buffer, and ECL are all new and noncontaminated. If the buffers are contaminated with sodium azide, it can inactivate HRP.

(3) Faint bands or weak signal: It can be caused by a low concentration of antibody or antigen. Increasing exposure time can also help to make the band clearer. Another reason could be nonfat dry milk masking the antigen. In this case, use BSA or decrease the amount of milk used.

(4) High background on the blot: It is often caused by the too high concentration of the antibody, which can bind to PVDF membranes. Another problem could be the buffers, which may be too old. Increasing the washing time can also help to decrease the background. Additionally, too high exposure can also lead to this problem. Therefore, it is advisable to check different exposure times to achieve an optimum time.

(5) Patchy or uneven spots on the blot: Improper transfer usually causes them. If there are air bubbles trapped between the gel and the membrane, it will appear darker on the film. It is also essential to use a shaker for all incubation so that there is no uneven agitation during the incubation. Once again, washing is of utmost importance as well to wash the background. Antibodies binding to the blocking agents can also cause this problem; in this case, another blocking agent should be tried. Filtering the blocking agent can also help to remove some contaminants. Finally, this problem can also be caused by the aggregation of the secondary antibody; in this case, the secondary antibody should be centrifuged and filtered to remove the aggregated.

(6) Which blocking buffer/blocking agent do I use? Non-fat milk or BSA?

Non-Fat Milk

Pros

• cheaper
• Blocks better than BSA
• Easy preparation

Cons

• Cannot be used with antibodies which target phosphoproteins
• Cannot be used with streptavidin-biotin-based systems as milk also contains biotin
• Lowers the sensitivity of some commercially available anti-His monoclonal antibodies

BSA

Pros

• Provides defined results – only one protein means lower risk of cross-reactivity
• As Albumin is not generally phosphorylated, it can be used with phosphoproteins.

Cons

• More expensive
• Not recommended for lectin probing as its carbohydrates may increase background

Storage temperatures and conditions

For many of our antibodies, freezing at -20 C or -80 C in small aliquots is the optimal storage condition. Aliquotting minimizes damage due to freezing and thawing, as well as contamination introduced by pipetting from a single vial multiple times. Aliquots should be no smaller than 10 µl.

Upon receiving the antibody, centrifuge at 5,000 x g for 30 seconds to pull down the solution, and transfer aliquots into low-protein-binding microcentrifuge tubes. Antibodies should be frozen as soon as possible, storage at 4 C upon receipt of the antibody is acceptable for one to two weeks, followed by freezing for long-term storage.

To prevent microbial contamination, sodium azide can be added to an antibody preparation to a final concentration of 0.02% (w/v). If using antibodies for in vivo studies, please be sure to use preparations that do not contain sodium azide. This antimicrobial agent blocks the cytochrome electron transport system. Sodium azide will interfere with any conjugation that involves an amine group and should be removed before proceeding with the conjugation. After conjugation, antibodies can be stored in sodium azide but 0.01%  thimerosal (Merthiolate), which does not have a primary amine, is an acceptable alternative.

Sodium azide can be removed from antibody solutions by dialysis or gel filtration. The molecular weight of IgG is 150,000 daltons (IgM is ~ 600,000); the molecular weight of sodium azide is 65 daltons. A micro-dialysis unit with a cut off at 14,000 daltons will retain the antibody as the azide diffuses out. In a beaker on a magnetic stirrer kept at 4 C, use at least a liter of cold PBS per ml of antibody and stir the dialysis unit for 6 hrs. Change the PBS twice, stirring at least 6 hrs for each change. If possible, all materials should be sterilized and the resulting preparation should be handled aseptically.

Freeze/thaw damage

Repeated freeze/thaw cycles can denature an antibody, causing it to form aggregates that reduce the antibody’s binding capacity.

Storing at -20 C should be adequate for most antibodies; there is no appreciable advantage to storing at -80 C. The freezer must not be of the frost-free variety. These cycle between freezing and thawing (to reduce frost-build-up), which is exactly what should be avoided. For the same reason, antibody vials should be placed in an area of the freezer that has minimal temperature fluctuations, for instance towards the back rather than on a door shelf.

Some researchers add the cryoprotectant glycerol to a final concentration of 50% to prevent freeze/thaw damage; glycerol will lower the freezing point to below -20 C. While this may be acceptable for many antibodies, only a small percentage of the antibodies we offer have been tested for stability in this storage condition and our guarantee only applies to antibodies stored as recommended on the datasheet. Storing solutions containing glycerol at -80 C is not advised since this is below the freezing point of glycerol. Please be aware that glycerol can be contaminated with bacteria. If adding glycerol or any cryoprotectant, care should be taken to obtain a sterile preparation.

Diluting antibodies to working concentration and storing at 4 C for more than a day should be avoided. Proteins, in general, are less susceptible to degradation when stored at higher concentrations, ideally 1 mg/ml or higher. This is the rationale for including proteins such as BSA in the antibody solution as stabilizers. The added protein also serves to minimize loss of antibody due to binding to the vessel wall. For antibodies that one intends to conjugate, stabilizing proteins should not be added since they will compete with the antibody and reduce the efficiency of the conjugation.